Patients will be administered oral capsules once daily for ten consecutive days. Credit: New Africa via Shutterstock.com.

The IMCA centre’s ethics committee in Israel has approved Clearmind Medicine’s CM-CMND-001 Phase I/II clinical trial of MEAI-based CMND-100 compound to treat alcohol use disorder (AUD).

The single and multiple-dose, multinational, multi-centre study is designed to evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in healthy volunteers and AUD subjects.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Finding the tolerable dose and describing the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated CMND-100 doses in healthy subjects and those with AUD is the primary endpoint of the study.

Evaluation of CMND-100’s efficacy in the reduction of drinking patterns and craving, in moderate-to-severe AUD subjects is the secondary endpoint.

Patients will be administered oral capsules once daily for ten consecutive days. During the trial period, they will report their drinking patterns and craving for alcohol and cigarettes.

Sheba Medical Center in the Tel Aviv suburb of Ramat Gan Psychiatric Division head professor Mark Weiser will lead the study.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clearmind CEO Dr Adi Zuloff-Shani said, “CMND-100 was shown to cause a significant and immediate reduction of alcohol cravings and consumption in pre-clinical studies with a high safety profile.

“As a result, we believe that CMND-001 holds tremendous potential as an alternative to current approaches. Moreover, CMND-100 is intended as a once-a-day oral capsule that can be taken from the privacy of one’s home.

“With CMND-100, we aim to revolutionise AUD treatment and improve patients’ compliance to therapy compared to other marketed pharmacotherapies.”

The company plans to expand the study to two additional sites in the US, upon signing an agreement with local sites.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now